Evidence map›Paper›PMID 31465250›Full record

ArticleJournal of oncology practice2019

Estimated Cost and Savings in a Patient Management Program for Oral Oncology Medications: Impact of a Split-Fill Component.

Francis C Staskon, Heather S Kirkham, Amy Pfeifer, Richard T Miller

Abstract read
In one paragraph

Article in Journal of oncology practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. The impact of early oral anticancer medication monitoring through electronic patient assessments.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
    Trial
  2. Article
  3. Article
  4. Optimising oncology drug expenditure in Ireland.Irish journal of medical science · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Francis C StaskonWalgreen Company, Deerfield, IL.
Heather S KirkhamWalgreen Company, Deerfield, IL.
Amy PfeiferAllianceRx Walgreens Prime, Orlando, FL 32819.
Richard T MillerAllianceRx Walgreens Prime, Orlando, FL 32819.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA national specialty pharmacy implemented a split-fill option within an oral oncology patient management program to reduce pharmacy costs and medication wastage resulting from early discontinuations. Payers covered dispensed medications at half-quantity intervals for each dispense up to 3 months. Proactive outreach to patients before they had used up the initial dispensed medication quantity helped assess the patient's tolerance to the new medication and adverse effects. This study compared costs for patients with a split-fill option to similar costs for patients without this option taking into account patient discontinuation rates, patient-reported adverse effects rates, estimated pharmacy costs, and potential wastage.

methodsThis retrospective cohort study included patients who were new to therapy on a split-fill medication between September 2015 and August 2017. A 1:1 greedy match algorithm was conducted using propensity variables to match patients from each cohort. Per-month discontinuation rates were determined for both split-fill and non-split-fill groups. The non-split-fill potential wastage was calculated as monthly costs for discontinuations in the following month and weighted by split-fill discontinuation rates.

resultsOf the 2,363 program patients who met selection criteria for the 11 medications, 671 patients from each group were matched. Payers with a split-fill program had significant medication savings per covered month ($2,147.60 at 1 month) and at a cumulative 6 months. Modeled wastage indicated that payers without a split-fill program could expect to save $2,646.74 monthly by using this option. Both cohorts had similar rates of adverse effects and time until first reported adverse effect.

conclusionIn the first 6 months, the split-fill patient managed program had lower discontinuation rates, significantly reduced pharmacy costs, and reduced potential wastage.

Indexed as

Cost SavingsHealth Care CostsMedical OncologyAdministration, OralAntineoplastic AgentsDisease ManagementHumansMedication AdherenceNeoplasmsOutcome Assessment, Health CarePharmaceutical ServicesPropensity ScoreRetrospective StudiesTime FactorsAntineoplastic Agents

Identifiers

PMID31465250
PMCPMC6790878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.